Serious cardiovascular adverse events with fluoroquinolones versus other antibiotics: A self‐controlled case series analysis-Reference-Cited by-同舟云学术

Serious cardiovascular adverse events with fluoroquinolones versus other antibiotics: A self‐controlled case series analysis

Published:2020-10-12 Issue:6 Volume:8 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol. Res. Perspect.

Author:

Aspinall Sherrie L.¹²^ORCID,Sylvain Nathan P.³,Zhao Xinhua²,Zhang Rongping¹,Dong Diane¹,Echevarria Kelly⁴,Glassman Peter A.¹⁴⁵,Goetz Matthew Bidwell⁵⁶,Miller Donald R.⁷,Cunningham Francesca E.¹

Affiliation:

1. VA Center for Medication Safety Hines IL USA

2. VA Center for Health Equity Research and PromotionVA Pittsburgh Healthcare System Pittsburgh PA USA

3. White River Junction VA Medical CenterWhite River Junction VT USA

4. VA Pharmacy Benefits Management Services Washington DC USA

5. David Geffen School of Medicine at UCLA Los Angeles CA USA

6. VA Greater Los Angeles Healthcare System Los Angeles CA USA

7. VA Center for Healthcare Organization & Implementation Research Bedford MA USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.664

Reference21 articles.

1. Inpatient fluoroquinolone stewardship improves the quantity and quality of fluoroquinolone‐prescribing at hospital discharge: a retrospective analysis among 122 Veterans Health Administration Hospitals;Suzuki H;Clin Infect Dis,2019

2. A report of the efforts of the veterans health administration national antimicrobial stewardship initiative;Kelly AA;Infect Control Hosp Epidemiol,2017

3. In brief: more fluoroquinolone warnings;Med Lett Drugs Ther,2018

4. FDA Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 12–20‐2018.https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐warns‐about‐increased‐risk‐ruptures‐or‐tears‐aorta‐blood‐vessel‐fluoroquinolone‐antibiotics(accessed December 16 2019)

5. Self controlled case series methods: an alternative to standard epidemiological study designs

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms;European Journal of Vascular and Endovascular Surgery;2024-02

2. Lack of association between fluoroquinolone and aortic aneurysm or dissection;European Heart Journal;2023-09-19

3. Do fluoroquinolones increase aortic aneurysm or dissection incidence and mortality? A systematic review and meta-analysis;Frontiers in Cardiovascular Medicine;2022-08-09

4. Inclusion of unexposed subjects improves the precision and power of self-controlled case series method;Journal of Biopharmaceutical Statistics;2021-11-15

5. Current progress of fluoroquinolones-increased risk of aortic aneurysm and dissection;BMC Cardiovascular Disorders;2021-09-28